# Mirabegron

## Betmiga 50mg prolonged-release

| TAH Drug Code      | [OBET5](https://www.tahsda.org.tw/drugs/hissearch.php?drug_code=OBET5)                                                                                                                                                                                                                                                                                                                                                                     |
|:-------------------|:-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Indications        | Neurogenic detrusor overactivity. Overactive bladder, Monotherapy or in combination with solifenacin, with symptoms of urge urinary incontinence, urgency, and urinary frequency.                                                                                                                                                                                                                                                          |
| Dosing             | 25-50 mg once daily. May be taken with or without food. Swallow whole, do not chew, divide or crush.                                                                                                                                                                                                                                                                                                                                       |
| Hepatic Impairment | Dose adjustment required                                                                                                                                                                                                                                                                                                                                                                                                                   |
| Renal Impairment   | Dose adjustment required                                                                                                                                                                                                                                                                                                                                                                                                                   |
| Contraindications  | Hypersensitivity to mirabegron or any components of the product.                                                                                                                                                                                                                                                                                                                                                                           |
| Adverse Effects    | Common Cardiovascular: Hypertension (7% to 11.3% ), Tachycardia (1.2% to 2.2% ) Gastrointestinal: Constipation (1.2% to 4.7% ), Xerostomia (2.8% to 9.3% ) Neurologic: Headache (1.6% to 4.1% ) Renal: Urinary tract infectious disease (Adult, 2.9% to 8.4% ; pediatric, 24.4% ) Respiratory: Nasopharyngitis (3.5% to 5.8% ) Serious Neurologic: Cerebrovascular accident (0.4% ) Renal: Urinary retention Other: Cancer (0.1% to 1.3% ) |
| Pregnancy          | No (Limited) Human Data â€“ Animal Data Suggest Low Risk                                                                                                                                                                                                                                                                                                                                                                                     |
| Lactation          | No (Limited) Human Data - Potential Toxicity                                                                                                                                                                                                                                                                                                                                                                                               |
| More Info          | [UpToDate](https://www.uptodate.com/contents/mirabegron-drug-information)                                                                                                                                                                                                                                                                                                                                                                  |

